#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

CHICA­GO — While the lat­er-stage drug de­vel­op­ers in the ge­o­graph­ic at­ro­phy field are near the fin­ish line, John­son & John­son’s Janssen is tak­ing a more de­lib­er­ate route, with a treat­ment that it hopes to be a one-time fix.

The Big Phar­ma will take its Hemera Bio­sciences-ac­quired gene ther­a­py in­to a Phase II study lat­er this year in pa­tients with GA, a com­mon form of age-re­lat­ed mac­u­lar de­gen­er­a­tion that im­pacts about five mil­lion peo­ple world­wide. To get there, Janssen tout­ed ear­ly-stage safe­ty da­ta at the Amer­i­can Acad­e­my of Oph­thal­mol­o­gy an­nu­al con­fer­ence Sat­ur­day morn­ing, half a day af­ter com­peti­tors Apel­lis and Iver­ic Bio re­vealed their own more-de­tailed Phase III analy­ses.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER